• According to a report from Bloomberg, Valeant Pharmaceuticals (NYSE:VRX) made a hostile bid to acquire Cephalon (NASDAQ:CEPH) for about $73 a share in cash or about $5.7 billion, after earlier bids were rejected • Standard & Poor’s said the world’s biggest asset manager BlackRock Inc (NYSE:BLK) would replace Genzyme Corp. (NASDAQ:GENZ) in the S&P 500 index [...] (ACXM) Company News for March 31, 2011 – Corporate Summary